Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Clin Oncol. Sep 24, 2021; 12(9): 800-807
Published online Sep 24, 2021. doi: 10.5306/wjco.v12.i9.800
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Overall survival of 88 patients with Hodgkin’s lymphoma.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Overall survival of 88 patients with Hodgkin’s lymphoma treated with either MOPP or ABVD (A) and treated either with or without hematopoietic stem cell transplants (B). ABVD: adriamycin bleomycin vinblastine and dacarbazine; HSCT: Hematopoietic stem cell transplant; MOPP: mechlorethamine, Oncovin, procarbazine, and prednisone.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Overall survival of 88 patients with Hodgkin’s lymphoma with or without relapsed or refractory disease (A), and overall survival of the patients with Hodgkin’s lymphoma classified as described by Diefenbach et al (B).
  • Citation: Sánchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Córdova-Ramírez AC, Rivera-Álvarez M, León-Peña A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Long-term results of the treatment of Hodgkin’s lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol 2021; 12(9): 800-807
  • URL: https://www.wjgnet.com/2218-4333/full/v12/i9/800.htm
  • DOI: https://dx.doi.org/10.5306/wjco.v12.i9.800